$11.13
0.00%
Nasdaq, Mon, Aug 04 2025
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$11.13
-0.15 1.33% 1M
+3.07 38.09% 6M
+5.49 97.34% YTD
+5.16 86.43% 1Y
-14.97 57.36% 3Y
-20.79 65.13% 5Y
-20.79 65.13% 10Y
-20.79 65.13% 20Y
Nasdaq, Closing price Mon, Aug 04 2025
+0.00 0.00%
ISIN
US92539P1012
Symbol
VERV
Industry

Key metrics

Basic
Market capitalization
$992.2m
Enterprise Value
$495.1m
Net debt
positive
Cash
$497.1m
Shares outstanding
88.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.6 | 21.1
EV/Sales
8.3 | 10.5
EV/FCF
negative
P/B
2.1
Financial Health
Equity Ratio
76.2%
Return on Equity
-40.3%
ROCE
-37.1%
ROIC
-225.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$59.6m | $47.1m
EBITDA
$-201.6m | $-272.4m
EBIT
$-208.5m | $-254.3m
Net Income
$-181.0m | $-225.8m
Free Cash Flow
$-147.0m
Growth (TTM | estimate)
Revenue
271.4% | 45.6%
EBITDA
6.5% | -22.8%
EBIT
6.0% | -11.2%
Net Income
8.0% | -13.6%
Free Cash Flow
1.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-338.2% | -578.8%
EBIT
-349.7%
Net
-303.6% | -479.7%
Free Cash Flow
-246.6%
More
EPS
$-2.0
FCF per Share
$-1.7
Short interest
4.8%
Employees
255
Rev per Employee
$130.0k
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Verve Therapeutics Inc forecast:

6x Buy
43%
8x Hold
57%

Analyst Opinions

14 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
43%
Hold
57%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
271% 271%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
12% 12%
97%
- Research and Development Expense 210 210
13% 13%
353%
-202 -202
7% 7%
-338%
- Depreciation and Amortization 6.84 6.84
15% 15%
11%
EBIT (Operating Income) EBIT -208 -208
6% 6%
-350%
Net Profit -181 -181
8% 8%
-304%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Neutral
PRNewsWire
18 days ago
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Neutral
PRNewsWire
19 days ago
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tr...
Positive
MarketBeat
22 days ago
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement.
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 255
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today